Roche Holding AG

Roche Holding AG CEO Thomas Schinecker is optimistic about the company's latest Alzheimer’s drug, which has shown effectiveness in breaking up amyloid plaques. The drugmaker presented its data at the CTAD medical conference. Roche's third-quarter sales rose 9% to 15.1 billion Swiss francs, driven by key medicines. The company confirmed its forecast for high-single-digit adjusted earnings per share growth.

Global Organoids Market to grow at a CAGR of ~14% by 2030, driven by personalized medicine, organoid use in drug discovery, and cancer research. North America leads the market, with key players including Thermofisher Scientific Inc., StemCell Technologies Inc., and others. Organoids mimic human organs, aiding in disease modeling and drug testing, but face challenges like high costs and limited vascularization.

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report highlights 75+ companies developing 80+ therapies, including promising candidates like GA Depot, Remibrutinib, and IMU 838. Key events include Immunic's positive Phase 3 ENSURE trial interim analysis, Roche's FDA approval for Ocrevus injectable, and Sanofi's mixed results for tolebrutinib in Phase III trials. The report covers global pipeline stages, product types, molecule types, mechanisms of action, and routes of administration.

Jonathan Dickinson, with extensive biotech and pharma experience, joins Innate Pharma. Previously at Incyte, ARIAD Pharmaceuticals, Bristol-Myers Squibb, and Hoffmann-La Roche, he started at Novartis. Dickinson holds a Bachelor of Science in Genetics and an MBA from the University of Nottingham. Hervé Brailly will advise for a smooth transition and may join the Board.

The biotechnology reagents market is projected to grow from $86.17 billion in 2024 to $124.95 billion in 2028 at a CAGR of 9.7%, driven by factors like biopharmaceutical development, genomics research, and the rise of PCR technology.

The weight management market is rapidly expanding, with SNS Insider projecting a 43.73% annual growth rate through 2032. Major pharmaceutical companies like Novo Nordisk, Eli Lilly, and Roche are entering the market, anticipating a 15-fold increase in obesity drug sales over five years. PlantX Life Inc. has partnered with LIV3 to launch SugarShield, a plant-based weight loss supplement targeting the $5.24bn market. Novo Nordisk's SOUL trial showed oral semaglutide reduced MACE by 14% in type 2 diabetes patients, while Eli Lilly is suing vendors for selling copycat tirzepatide. Viking Therapeutics and Roche are also advancing in obesity drug development.

PlantX Life Inc. announces joint venture with LIV3 to launch SugarShield supplement, targeting the $5.24 billion weight loss management market. The supplement aims to boost energy, curb cravings, and simplify weight management without restrictive diets, leveraging PlantX's expertise in branding and digital platforms.

Astellas Pharma Inc. received U.S. FDA approval for Vyloy (zolbetuximab-clzb), a first-in-class CLDN18.2-targeted treatment for first-line therapy in adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. Vyloy, a CLDN18.2-directed cytolytic antibody, is used with fluoropyrimidine- and platinum-containing chemotherapy for CLDN18.2-positive tumors as determined by the VENTANA CLDN18 (43-14A) RxDx Assay. The approval follows a complete response letter in January, and Vyloy has also been approved in Japan, the U.K., the EU, and South Korea.

DelveInsight's 'Hemophilia A Pipeline Insight 2024' covers global Hemophilia A therapies, highlighting over 40+ pipeline therapies, key companies like Spark Therapeutics, Pfizer, and Sanofi, and recent FDA approvals for Roctavian and ALTUVIIIO. The report assesses the therapeutic landscape, including product types, stages, routes of administration, and molecule types.